This page uses JavaScript for CSS
Home
|
About CDC
|
Press Room
|
A-Z Index
|
Contact Us
CDC en Español
Search:
CDC Home
>
HIV/AIDS
>
Questions and Answers
Topics
African Americans
Basic Information
Funding
Global HIV/AIDS
Hispanics/Latinos
Men Who Have Sex with Men (MSM)
Statistics & Surveillance
Testing
Women
More Topics...
Resources by Format
Questions & Answers
Fact Sheets
Brochures
Slide Sets
Podcasts
Software
Journal Articles
Reports
Recommendations & Guidelines
Other Documents
LEGEND:
Link to a PDF document
Link to non-governmental site and does not necessarily represent the views of the CDC
Adobe Acrobat (TM) Reader needs to be installed on your computer in order to read documents in PDF format.
Download the Reader
.
CDC’s Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention
View PDF
Revised August 2008
Research Rationale
Why is CDC launching trials of pre-exposure prophylaxis for HIV prevention?
How would HIV treatment drugs work to protect against HIV infection?
What data suggest that this approach may be safe and effective?
Why study two different drugs?
Trial Designs and Objectives
What specific CDC studies are under way or planned?
What other issues will the trials examine?
When will the trials begin and how are they designed?
Why have these populations been selected to take part in the trials?
Who will be eligible to participate in the PrEP trials?
What is the University of Washington Partners PrEP Study and how is CDC involved?
Are similar trials being conducted else where?
Why are there so many different trials currently ongoing?
What is the cost of the CDC studies of PrEP?
Safeguards and Services for Trial Participants
What safeguards are in place to ensure protection of the volunteers?
Will trial participants increase their risk behavior when they begin taking daily pills?
How will CDC evaluate the impact of PrEP if participants reduce their risk behavior?
What will happen to participants who do become infected during the trial?
What are the most common side effects associated with the drugs being tested?
Will healthcare be provided for any health problems related to the drug?
Community Involvement
What is being done to solicit input from the communities in which these trials will be conducted?
Anticipated Results and Impact
When will the results of the trials be available?
If PrEP does prove to be effective at preventing HIV infection in this trial, how will the drugs be made available to people who need or want it?
If the drugs prove safe and effective in one population, will they work equally well in other populations?
If studies show that PrEP reduces the risk of HIV transmission, will people still have to practice other risk-reduction behaviors for HIV?
Will support for these trials take away funding from behavioral interventions?
Are physicians in certain places already prescribing the drugs being studied for HIV prevention?
Go to top
Last Modified: August 3, 2008
Last Reviewed: August 3, 2008
Content Source:
Divisions of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Printer-Friendly Version
What's New?
HIV/AIDS A-Z Index
VIH/SIDA en español
CDC Responds to HIV/AIDS
HIV/AIDS E-Publications
Get E-mail Updates
Order Free HIV/AIDS Publications
RSS
|
RSS Help
Media
Conferences and Trainings
Key Resources
Site Map
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day -
cdcinfo@cdc.gov